Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 Aug 11;17:336.
doi: 10.1186/s12891-016-1174-9.

An Initial Loading-Dose Vitamin D Versus Placebo After Hip Fracture Surgery: Randomized Trial

Affiliations
Free PMC article
Randomized Controlled Trial

An Initial Loading-Dose Vitamin D Versus Placebo After Hip Fracture Surgery: Randomized Trial

Jenson Cs Mak et al. BMC Musculoskelet Disord. .
Free PMC article

Abstract

Background: Improving vitamin D (25-OHD) status may be an important modifiable factor that could reduce disability severity, fall-rates and mortality associated after hip fracture surgery. Providing a loading-dose post-surgery may overcome limitations in adherence to daily supplementation.

Method: In this randomized, double-blind, placebo-controlled trial, 218 adults, aged 65-years or older, requiring hip fracture surgery were assigned to receive a single loading-dose of cholecalciferol (250,000 IU vitamin-D3, the REVITAHIP - Replenishment of Vitamin D in Hip Fracture strategy) or placebo, both receiving daily vitamin-D(800 IU) and calcium (500 mg) for 26-weeks. Outcome measures were 2.4 m gait-velocity, falls, fractures, death (Week-4), 25-OHD levels, quality-of-life measure (EuroQoL) and mortality at weeks-2, 4 and 26.

Results: Mean age of 218 participants was 83.9(7.2) years and 77.1 % were women. Baseline mean 25-OHD was 52.7(23.5)nmol/L, with higher levels at Week-2 (73 vs 66 nmol/L; p = .019) and Week-4 (83 vs 75 nmol/L; p = .030) in the Active-group, but not at Week-26. At week-4, there were no differences in 2.4 m gait-velocity (0.42 m/s vs 0.39 m/s, p = .490), fractures (2.7 % vs 2.8 %, p = .964) but Active participants reported less falls (6.3 % vs 21.1 %, χ(2) = 4.327; p = 0.024), with no significant reduction in deaths at week-4 (1 vs 3, p = 0.295), higher percentage reporting 'no pain or discomfort' (96.4 % vs 88.8 %, p = 0.037), and trended for higher EuroQoL-scores (p = 0.092) at week-26. One case of hypercalcemia at week-2 normalised by week-4.

Conclusion: Among older people after hip fracture surgery, the REVITAHIP strategy is a safe and low cost method of improving vitamin-D levels, reducing falls and pain levels.

Trial registration: The protocol for this study is registered with the Australian New Zealand Clinical Trials Registry ANZCTRN ACTRN12610000392066 (Date of registration: 14/05/2010).

Keywords: Falls; Hip fracture; Randomized controlled trial; Rehabilitation; Vitamin D.

Figures

Fig. 1
Fig. 1
Enrolment and Flow of the Patients from REVITAHIP
Fig. 2
Fig. 2
Mean 25-hydroxyvitamin D levels over 26 weeks (* significance noted at Week 2 and 4)
Fig. 3
Fig. 3
Cumulative number of falls over 4 weeks (** denotes statistical difference)
Fig. 4
Fig. 4
Fall, Fractures and Deaths over 4 weeks by Intervention Group (** denotes statistical difference)

Similar articles

See all similar articles

Cited by 3 articles

References

    1. Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA. 2009;301(5):513–21. doi: 10.1001/jama.2009.50. - DOI - PubMed
    1. Cummings SR, Rubin SM, Black D. The future of hip fractures in the United States: numbers, costs, and potential effects of postmenopausal estrogen. Clin Orthop. 1990;252(1):163–166. - PubMed
    1. Kanis J, Johnell O, Oden A. Smoking and fracture risk: a meta-analysis. Osteoporosis Int. 2005;16(2):155–162. doi: 10.1007/s00198-004-1640-3. - DOI - PubMed
    1. Frost SA, Nguyen ND, Black DA, et al. Risk factors for in-hospital post-hip fracture mortality. Bone. 2011;49:553. doi: 10.1016/j.bone.2011.06.002. - DOI - PubMed
    1. Kannegaard PN, van der Mark S, Eiken P, Abrahamsen B. Excess mortality in men compared with women following a hip fracture. National analysis of comedications, comorbidity and survival. Age Ageing. 2010;39(2):203–209. doi: 10.1093/ageing/afp221. - DOI - PubMed

Publication types

MeSH terms

Feedback